To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter focuses on the various study designs used to estimate long-term treatment effects of disease-modifying therapies (DMTs) in multiple sclerosis (MS). It also discusses their strengths and weaknesses and the methodological challenges. Results suggest that sustained early treatment in MS patients can delay progression to significant disability and the studies support the concept that early treatment with DMTs has long-lasting effects. Long-term follow-up of patients have significant limitations, including loss of randomization and blinding, incomplete ascertainment, and the absence of an appropriate comparator. Long-term non-randomized observational trials (NROTs) include a wide range of study designs, such as prospective and retrospective cohort studies, case-control studies, and cross-sectional studies, with the common feature that any intervention studied is determined by clinical practice and not by the protocol. Several epidemiological and statistical methods are available to deal with confounding, in both design and analytical phases of NROTs.
Email your librarian or administrator to recommend adding this to your organisation's collection.